In a large retrospective cohort study including over 1.6 million patients with Type 2 Diabetes, with no prior diagnosis of obesity associated cancers, a significantly reduced risk in 10 out of 13 obesity associated cancers was reported with the use of GLP-1 agonists, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, pancreatic cancer, meningioma, and multiple myeloma 17
Results help your doctor determine whether standard semaglutide is ideal for your genetics, or whether an alternative compound like tirzepatide may produce better outcomespersonalizing your therapy beyond standard dosing
Staying hydrated and replenishing electrolytes is also crucial to prevent dehydration-related fatigue
Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN